Moses Lake Pharmacy Recalls Hydroxyprogesterone Caproate Oil Due to Sterility Concerns
JD & SN Inc. is recalling specific syringes of Hydroxyprogesterone Caproate Oil because the FDA cannot ensure the sterile compounded drugs are free from contamination.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' severity score under the rubric for significant injury or property damage reports or high-risk scenarios.
Plain-English summary
JD & SN Inc., doing business as Moses Lake Professional Pharmacy, is recalling specific syringes of Hydroxyprogesterone Caproate Oil, injectable Solution, 250 mg/mL. The recall covers various syringe sizes, including 4 mL, 5 mL, 6 mL, 10 mL, 16 mL, 18 mL, 20 mL, and 22 mL. The affected products were distributed nationwide.
The recall was initiated due to a lack of assurance of sterility. The FDA has determined that it cannot guarantee that all sterile human compounded drugs within their expiration dates are free from contamination. This classification is designated as FDA Class II.
Patients who have received this medication should contact their healthcare provider for further instructions. The recall is limited to the specific lot codes and quantities listed in the official FDA documentation.
The recalled product
- Product
- HYDROXYPROGESTERONE CAPROATE OIL, injectable Solution, 250 mg/mL, syringe sizes: 4 mL; 5 mL; 6 mL; 10 mL; 16 mL; 18 mL; 20 mL; and 22 mL, Rx only, JD & SN Inc, DBA Moses Lake Professional Pharmacy, 1555 S. Pilgrim St. Moses Lake WA 98837, (509)764-2314
- Category
- Drug — Injectable Solution
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- t12182014@7
- t12052014@12
- t10312014@21
- t10102014@21
- t10072014@6
- t09172014@30
- t09152014@11
- t08132014@13
- t08112014@28
- t07282014@28
- t07282014@16
- t07012015@7
- t06302015@31
- t06222015@17
- t06112015@14
- t06022015@17
- t05182015@24
- t05152015@19
- t05072015@9
- t04272015@19
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 101 recalled by JD & SN Inc., dba Moses Lake Professional Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 101 products in this recall →Related recalls
Same manufacturer · JD & SN Inc., dba Moses Lake Professional Pharmacy
See all →- SevereFDA Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Sodium Tetradecyl Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Six Trimix Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereMoses Lake Pharmacy Recalls Compounded Chorionic Gonadotropin Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Compounded Progesterone Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighFDA Recalls Hydroxyprogesterone Caproate Injectable Due to Compounding Conditions
FDA (Drugs) · 2019-04-17
- SevereHydroxyprogesterone Caproate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2021-11-03
- Severe
- SevereFDA Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2019-07-17
- SevereHydroxyprogesterone Caproate Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- ModerateRX3 Pharmacy Recalls Hydroxyprogesterone Caproate Syringes Due to Crystallization
FDA (Drugs) · 2014-03-26